Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Stuart Goldberg, MD, Mauricette Michallet, MD PhD, Rudiger Hehlmann, MD, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Aimee Foreman, Brian Calimlim, Ron Paquette, MD, Bengt Simonsson, MD, Carlo Gambacorti, MD PhD, Jorge E. Cortes, MD, Aleksandra Zagorska, Yuanxin Rong, Michael J. Mauro, MD

Blood (2016) 128 (22): 937.

https://doi.org/10.1182/blood.V128.22.937.937

Published: 2016

Journal Articles

Patients with Chronic Myelogenous Leukemia May Not Want to Discontinue Tyrosine Kinase Inhibitor Therapy

Stuart Goldberg, MD, Stephanie Hamarman, MD

Blood (2015) 126 (23): 1584.

https://doi.org/10.1182/blood.V126.23.1584.1584

Published: 2015

Journal Articles

Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR 4.5 ) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update

Michael Mauro, MD, Jerald Radich, MD, Jorge E. Cortes, MD, Shaker Dakhil, MD, Christopher Keir, MD, Sandy Yi, Martha Wadleigh, MD, Vivian G. Oehler, MD, Thomas Ervin, MD, Stuart Goldberg, MD, Michael Savona, MD, FACP

Blood (2013) 122 (21): 4015.

https://doi.org/10.1182/blood.V122.21.4015.4015

Published: 2013

Journal Articles

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

Jorge E. Cortes, MD, Rüdiger Hehlmann, MD, Carlo Gambacorti-Passerini, MD, Stuart Goldberg, MD, H. Jean Khoury, MD, Michael Mauro, MD, Mauricette Michallet, MD, PhD, Ron Paquette, MD, PhD, Bengt Simonsson, MD, PhD, Aimee Foreman, PhD, Hesham Mohamed, MD, Teresa Zyczynski, Pharm.D., MPH, Ishan Hirji, MPH, Catherine Davis, Pharm.D.

Blood (2013) 122 (21): 4026.

https://doi.org/10.1182/blood.V122.21.4026.4026

Published: 2013

Journal Articles

Donor CD3 Chimerism After Allogeneic Transplantation Predicts Probability Of Relapse For Patients Treated For Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Non-Hodkgin's Lymphoma (NHL)

George Nahas, DO, Arpita P Gandhi, MD, Michele L. Donato, MD, Themba Nyirenda, PhD, David H. Vesole, MD, PhD, Andrew L Pecora, Stuart Goldberg, MD, Andre Goy, MD, Tatyana Feldman, MD, Anthony R. Mato, MD, Pritish K. Bhattacharyya, MD, Melissa Baker, APN, Phyllis McKiernan, APN, Brenda Diaz, APN, Scott D Rowley, MD, FACP

Blood (2013) 122 (21): 4545.

https://doi.org/10.1182/blood.V122.21.4545.4545

Published: 2013

Journal Articles

Why Don't Hematologists Follow Chronic Myeloid Leukemia Monitoring Guidelines? A Survey Of Practioners In New Jersey and Indiana

Stuart Goldberg, MD, Luke Akard, MD

Blood (2013) 122 (21): 5187.

https://doi.org/10.1182/blood.V122.21.5187.5187

Published: 2013

Journal Articles

A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents

Guillermo Garcia-Manero, MD, Selina M Luger, MD, Stuart Goldberg, MD, Jessica K Altman, MD, Martha Arellano, MD, Meir Wetzler, MD, Karen Seiter, MD, Judy Chiao, MD, Hagop M Kantarjian, MD

Blood (2013) 122 (21): 2752.

https://doi.org/10.1182/blood.V122.21.2752.2752

Published: 2013

Journal Articles

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Martin S Tallman, MD, Gary Schiller, MD, Denise Trone, Guy Gammon, MD, Stuart Goldberg, MD, Alexander E Perl, MD, Jean-Pierre Marie, MD, Giovanni Martinelli, Mark Levis, MD, PhD

Blood (2013) 122 (21): 494.

https://doi.org/10.1182/blood.V122.21.494.494

Published: 2013

Journal Articles

Combination Melphalan and Bortezomib Conditioning with Autologous Hematopoietic Stem Cell Support in Patients with Advanced Multiple Myeloma. A Phase I/II Study.

Scott D. Rowley, MD, FACP, David Siegel, MD, PhD, Michele L. Donato, MD, Andrew L. Pecora, MD, Tatyana Feldman, MD, Stuart Goldberg, MD, Andre Goy, MD, Aisha Masood, MD

Blood (2009) 114 (22): 1214.

https://doi.org/10.1182/blood.V114.22.1214.1214

Published: 2009

Journal Articles

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Jorge Romaguera, MD, Luis Fayad, Peter McLaughlin, MD, Barbara Pro, MD, Maria Alma Rodriguez, MD, Michael Wang, MD, Pamela Weaver, RN, Kimberly Hartig, Larry Kwak, MD, PhD, Tatyana Feldman, MD, Judy Smith, RN, Peggy Ford, RN, Stuart Goldberg, MD, Andrew Pecora, MD, Andre Goy, MD

Blood (2008) 112 (11): 3051.

https://doi.org/10.1182/blood.V112.11.3051.3051

Published: 2008

Journal Articles

A Phase 1 Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

Andre Goy, MD, Peggy Ford, Tatyana Feldman, MD, Andrew Pecora, Stuart Goldberg, MD, Michele Donato, David Siegel, David Panush, Mark S. Berger, MD

Blood (2007) 110 (11): 2569.

https://doi.org/10.1182/blood.V110.11.2569.2569

Published: 2007

Journal Articles

DCEP (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin) Followed by High-Dose G-CSF Is a Highly Efficient and Safe Regimen for Stem Cell Mobilization for Multiple Myeloma.

Jason P. Gonsky, MD, PhD, Nikoletta Lendvai, MD, PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Andrew L. Pecora, MD, Tatyana Feldman, MD, Andre Goy, MD, Stuart Goldberg, MD, David S. Siegel, MD, PhD

Blood (2007) 110 (11): 3284.

https://doi.org/10.1182/blood.V110.11.3284.3284

Published: 2007

Journal Articles

Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).

Lubomir Sokol, MD, PhD, Larry Cripe, M.D., Hagop Kantarjian, M.D., Mikkael A. Sekeres, M.D., Simrit Parmar, M.D., Peter Greenberg, M.D., Stuart Goldberg, M.D., Vikas Bhushan, M.D., Jamile Shammo, M.D., Raymond Hohl, M.D., Ph.D., Yu-Ping Li, Ph.D., Ann Lowe, M.D., Joy Zhu, M.D., Alan List, M.D.

Blood (2006) 108 (11): 2657.

https://doi.org/10.1182/blood.V108.11.2657.2657

Published: 2006

Journal Articles

Molecular Responses in Newly Diagnosed Chronic Myelocytic Leukemia (CML) Patients Treated with 800 mg Imatinib Daily: An Update from the RIGHT Trial Study Group.

Jorge Cortes, MD, Francis Giles, MD, August J. Salvado, MD, Karen McDougall, Jerald Radich, MD, Maher Albitar, MD, Bayard L. Powell, MD, Stuart Goldberg, MD, Hagop M. Kantarjian, MD

Blood (2006) 108 (11): 2149.

https://doi.org/10.1182/blood.V108.11.2149.2149

Published: 2006

Journal Articles

A Phase II Study of Enzastaurin, a Protein Kinase C-β (PKCβ) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Michael Robertson, Brad Kahl, Julie Vose, Sven de Vos, Mary Laughlin, Patrick Flynn, Kendrith Rowland, Jose Cruz, Stuart Goldberg, Christelle Darnstein, Nathan Enas, Donna Neuberg, Kerry Savage, Donald Thornton, Christopher Slapak, Margaret Shipp

Blood (2005) 106 (11): 934.

https://doi.org/10.1182/blood.V106.11.934.934

Published: 2005

Journal Articles

Interim Analysis of a Multicenter Trial of High Dose (HD) Imatinib in Newly Diagnosed Early Chronic Phase (CP) Patients (pt) with Chronic Myeloid Leukemia (CML).

Jorge Cortes, MD, Francis Giles, MD, August J. Salvado, MD, Karen McDougall, RN, Jerald Radich, MD, Mahir Albitar, MD, Bayard L. Powell, MD, Stuart Goldberg, MD, Hagop M. Kantarjian, MD, RIGHT Trial Study Group

Blood (2005) 106 (11): 1085.

https://doi.org/10.1182/blood.V106.11.1085.1085

Published: 2005

NARROW

Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Patients with Chronic Myelogenous Leukemia May Not Want to Discontinue Tyrosine Kinase Inhibitor Therapy

Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR 4.5 ) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

Donor CD3 Chimerism After Allogeneic Transplantation Predicts Probability Of Relapse For Patients Treated For Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Non-Hodkgin's Lymphoma (NHL)

Why Don't Hematologists Follow Chronic Myeloid Leukemia Monitoring Guidelines? A Survey Of Practioners In New Jersey and Indiana

A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

Combination Melphalan and Bortezomib Conditioning with Autologous Hematopoietic Stem Cell Support in Patients with Advanced Multiple Myeloma. A Phase I/II Study.

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

A Phase 1 Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

DCEP (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin) Followed by High-Dose G-CSF Is a Highly Efficient and Safe Regimen for Stem Cell Mobilization for Multiple Myeloma.

Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).

Molecular Responses in Newly Diagnosed Chronic Myelocytic Leukemia (CML) Patients Treated with 800 mg Imatinib Daily: An Update from the RIGHT Trial Study Group.

A Phase II Study of Enzastaurin, a Protein Kinase C-β (PKCβ) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Interim Analysis of a Multicenter Trial of High Dose (HD) Imatinib in Newly Diagnosed Early Chronic Phase (CP) Patients (pt) with Chronic Myeloid Leukemia (CML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only